JP2019507194A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507194A5 JP2019507194A5 JP2018566189A JP2018566189A JP2019507194A5 JP 2019507194 A5 JP2019507194 A5 JP 2019507194A5 JP 2018566189 A JP2018566189 A JP 2018566189A JP 2018566189 A JP2018566189 A JP 2018566189A JP 2019507194 A5 JP2019507194 A5 JP 2019507194A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- naphthyl
- heteroaryl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims 77
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 59
- 125000001624 naphthyl group Chemical group 0.000 claims 57
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 37
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims 36
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 36
- 229910052799 carbon Inorganic materials 0.000 claims 30
- 125000003342 alkenyl group Chemical group 0.000 claims 24
- 239000011669 selenium Substances 0.000 claims 22
- 125000003277 amino group Chemical group 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 125000003282 alkyl amino group Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 150000002367 halogens Chemical class 0.000 claims 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 18
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 18
- 229910052711 selenium Inorganic materials 0.000 claims 16
- -1 carboxy, naphthyl Chemical group 0.000 claims 15
- 125000004663 dialkyl amino group Chemical group 0.000 claims 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 13
- 150000001720 carbohydrates Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000000623 heterocyclic group Chemical class 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000003748 selenium group Chemical group *[Se]* 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 108010001498 Galectin 1 Proteins 0.000 claims 1
- 102000000802 Galectin 3 Human genes 0.000 claims 1
- 108010001517 Galectin 3 Proteins 0.000 claims 1
- 102100021736 Galectin-1 Human genes 0.000 claims 1
- 102000044445 Galectin-8 Human genes 0.000 claims 1
- 102100031351 Galectin-9 Human genes 0.000 claims 1
- 101710121810 Galectin-9 Proteins 0.000 claims 1
- 102000007563 Galectins Human genes 0.000 claims 1
- 108010046569 Galectins Proteins 0.000 claims 1
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662303872P | 2016-03-04 | 2016-03-04 | |
| US62/303,872 | 2016-03-04 | ||
| PCT/US2017/020658 WO2017152048A1 (en) | 2016-03-04 | 2017-03-03 | Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507194A JP2019507194A (ja) | 2019-03-14 |
| JP2019507194A5 true JP2019507194A5 (https=) | 2020-04-09 |
| JP7086008B2 JP7086008B2 (ja) | 2022-06-17 |
Family
ID=59744474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566189A Active JP7086008B2 (ja) | 2016-03-04 | 2017-03-03 | ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190367552A1 (https=) |
| EP (1) | EP3423461A4 (https=) |
| JP (1) | JP7086008B2 (https=) |
| KR (1) | KR102346913B1 (https=) |
| CN (1) | CN109071585B (https=) |
| AU (1) | AU2017228365B2 (https=) |
| CA (1) | CA3016343C (https=) |
| IL (2) | IL261431B (https=) |
| MX (1) | MX394409B (https=) |
| WO (1) | WO2017152048A1 (https=) |
| ZA (1) | ZA201805900B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3062648A1 (en) * | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| AU2018361991A1 (en) * | 2017-10-31 | 2020-05-14 | Galectin Sciences, Llc | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| AU2020214796A1 (en) * | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| CN114206893A (zh) * | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| CN113476442A (zh) * | 2021-07-28 | 2021-10-08 | 上海交通大学医学院附属第九人民医院 | 化合物gb-0139在治疗心肌梗死后心肌过度纤维化的药物中的应用 |
| JP2025511354A (ja) | 2022-04-06 | 2025-04-15 | シャペロン インク． | タウロデオキシコール酸又はその薬学的に許容される塩を有効成分として含有する肺線維症の予防又は治療用組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401301D0 (sv) * | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| CA2668693A1 (en) * | 2006-11-15 | 2008-05-22 | David E. Anderson | Therapeutic uses of tim-3 modulators |
| CN102439021B (zh) * | 2009-04-28 | 2015-09-02 | 格莱克特生物技术公司 | 半乳凝素的新型半乳糖苷抑制剂 |
| CA2794066C (en) * | 2012-10-31 | 2017-02-28 | Neil Henderson | Galactoside inhibitor of galectins |
| ES2869884T3 (es) * | 2011-09-16 | 2021-10-26 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico |
| AU2012363033B2 (en) * | 2011-12-28 | 2016-06-02 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
| EP2620443A1 (en) * | 2012-01-25 | 2013-07-31 | Galecto Biotech AB | Novel galactoside inhibitors of galectins |
| JP2015535233A (ja) * | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| WO2014078655A1 (en) * | 2012-11-15 | 2014-05-22 | Tufts University | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| JP2017512205A (ja) * | 2014-03-10 | 2017-05-18 | ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ | 腎臓障害を治療するための組成物及び方法 |
| EP3129032A1 (en) * | 2014-04-08 | 2017-02-15 | Galecto Biotech AB | Galactoside inhibitors for the treatment of alpha-synucleinopthies |
-
2017
- 2017-03-03 JP JP2018566189A patent/JP7086008B2/ja active Active
- 2017-03-03 EP EP17760896.5A patent/EP3423461A4/en active Pending
- 2017-03-03 CA CA3016343A patent/CA3016343C/en active Active
- 2017-03-03 CN CN201780027703.5A patent/CN109071585B/zh active Active
- 2017-03-03 US US16/080,423 patent/US20190367552A1/en not_active Abandoned
- 2017-03-03 MX MX2018010683A patent/MX394409B/es unknown
- 2017-03-03 AU AU2017228365A patent/AU2017228365B2/en active Active
- 2017-03-03 KR KR1020187028691A patent/KR102346913B1/ko active Active
- 2017-03-03 WO PCT/US2017/020658 patent/WO2017152048A1/en not_active Ceased
-
2018
- 2018-08-28 IL IL261431A patent/IL261431B/en active IP Right Grant
- 2018-09-03 ZA ZA2018/05900A patent/ZA201805900B/en unknown
-
2021
- 2021-03-17 IL IL281585A patent/IL281585B/en unknown
-
2022
- 2022-11-04 US US18/052,814 patent/US20230127345A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507194A5 (https=) | ||
| JP2020519625A5 (https=) | ||
| JPWO2023190748A5 (https=) | ||
| Prša et al. | The potential use of natural products to negate hepatic, renal and neuronal toxicity induced by cancer therapeutics | |
| JP2016515119A5 (https=) | ||
| JP2012509349A5 (https=) | ||
| JP2017535610A5 (https=) | ||
| JP2016513137A5 (https=) | ||
| JP2019510787A5 (https=) | ||
| JP2019522055A5 (https=) | ||
| JP2014508753A5 (https=) | ||
| JP2015528447A5 (https=) | ||
| JP2008531574A5 (https=) | ||
| JP2011527692A5 (https=) | ||
| JP2009515890A5 (https=) | ||
| JP2009521399A5 (https=) | ||
| JP2009534408A5 (https=) | ||
| JP2008502721A5 (https=) | ||
| US20220193106A1 (en) | Nucleobase analogue derivatives and their applications | |
| RU2020123899A (ru) | Новые соединения, ингибирующие mtor | |
| JP2017137323A5 (https=) | ||
| ES2529865B1 (es) | USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS | |
| MX2017011423A (es) | Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer. | |
| US9376432B2 (en) | Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma | |
| JP2008531713A5 (https=) |